January 21st 2025
The FDA has approved the supplemental New Drug Application for Spravato, the first and only monotherapy for adults with treatment-resistant depression.
January 17th 2025
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
IV Psilocin Benzoate for Major Depressive Disorder: New Phase 2a Results
December 18th 2024New positive topline results from an open-label phase 2a study of IV psilocin benzoate in patients with major depressive disorder showed that the treatment delivers rapid, lasting antidepressant effects for up to 3 months following a single dose.
Read More
Specter of Suicidality with Antiobesity Med Looms Despite Disparate Study Findings
September 24th 2024Reports of suicidality with GLP-1RA antiobesity medication are supported by analysis of WHO data, but no association is found in large population cohort study or analysis of clinical trials.
Read More
With MDMA on Hold, What’s Next for Psychedelics?
September 11th 2024The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.
Read More
Effects of Noninvasive Neurostimulation on Sleep Quality and Symptoms in Depression
September 6th 2024Will this help my sleep and mood? Researchers investigated the effects of noninvasive neurostimulation on sleep quality and depressive symptoms in patients with major depressive disorder in a meta-analysis of randomized controlled trials.
Read More